# Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants

> **NCT03188692** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 33 (actual)

## Conditions studied

- Immunization

## Interventions

- **BIOLOGICAL:** DPT-IPV-Hib (Combined Vaccine)

## Key facts

- **NCT ID:** NCT03188692
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-23
- **Primary completion:** 2017-11-02
- **Final completion:** 2018-08-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03188692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03188692, "Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03188692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*